Finkelstein Thompson LLP Announces Investigation of Clarient, Inc.
28 Ottobre 2010 - 12:49AM
Business Wire
Finkelstein Thompson LLP is investigating potential claims on
behalf of shareholders of Clarient, Inc. (“Clarient” or the
“Company”) (Nasdaq: CLRT) concerning the Company’s receipt of an
offer to purchase all outstanding common shares of the Company for
$5 per share and each outstanding preferred share for $20 by GE
Healthcare, Inc. The proposed offer is valued at approximately $580
million and is expected to close in late 2010 or early 2011.
The investigation is focused on the potential unfairness of the
transaction price to Clarient shareholders, the process by which
the Board of Directors considered the transaction, and potential
conflicts of interests among Clarient Board members. Stockholders
holding approximately 47% of Clarient’s current outstanding voting
stock have agreed to tender their shares in the proposed offer,
about 35% of which is held by insiders and major shareholders of
the Company. Additionally, according to Yahoo! Finance, at least
one analyst has set a target price of $6 for Clarient stock.
If you are interested in discussing your rights as a Clarient
shareholder, or have information relating to this investigation,
please contact Finkelstein Thompson's Washington, DC offices at
(877) 337-1050 or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients
in financial litigation, and has been appointed as lead or co-lead
counsel in dozens of shareholder class actions. Indeed, the firm
has served in leadership roles in cases that have recovered over $1
billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our
web site at www.finkelsteinthompson.com. Attorney advertising.
Prior results do not guarantee similar outcomes.
Grafico Azioni Clarient, Inc. (MM) (NASDAQ:CLRT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Clarient, Inc. (MM) (NASDAQ:CLRT)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Clarient, Inc. (MM) (NASDAQ): 0 articoli recenti
Più Finkelstein Thompson LLP Articoli Notizie